Liberostin

Cytisinicline, the active ingredient in Liberostin, is a nicotinic acetylcholine receptor partial agonist presented as an oral formulation for oral use. It is used to aid smoking cessation in adult smokers.

GNH USA supplies Liberostin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liberostin is a nicotinic acetylcholine receptor partial agonist indicated for smoking‑related disorders.

- Smoking cessation: helps adult smokers reduce nicotine withdrawal symptoms and increase the likelihood of quitting. - Tobacco dependence: supports individuals attempting to discontinue regular tobacco use. - Nicotine addiction: alleviates cravings associated with nicotine dependence.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headaches. - Insomnia: difficulty falling or staying asleep. - Abnormal dreams: vivid or unpleasant dreams. - Dry mouth: reduced salivation. - Gastrointestinal discomfort: mild abdominal cramping.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Mood changes: depression, anxiety, or irritability. - Cardiovascular events: palpitations or increased heart rate. - Severe nausea/vomiting: persistent and leading to dehydration. - Respiratory distress: wheezing or bronchospasm. - Suicidal ideation: thoughts of self‑harm.

Before initiating Liberostin, consider the following precautions: - Cardiovascular assessment: evaluate heart disease history before use. - Psychiatric monitoring: watch for mood alterations or depressive symptoms. - Liver function: adjust use in patients with severe hepatic impairment. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Potential drug interactions should be reviewed prior to therapy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertensive crisis. - Other nicotine replacement products: can lead to excessive nicotinic stimulation. - Certain antidepressants (e.g., bupropion): may potentiate central nervous system effects.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may alter plasma levels of Cytisinicline. - Alcohol: can exacerbate dizziness or nausea. - Antihypertensive agents: monitor blood pressure for additive effects.